enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Alnylam Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Alnylam_Pharmaceuticals

   Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics [3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. [4]

3. Christoph Westphal - Wikipedia

   en.wikipedia.org/wiki/Christoph_Westphal

   As of 2016 Alnylam remained the dominant company in the RNAi field. [ 12 ] [ 13 ] Alnylam has achieved approval for 5 medicines. In 2003 he co-founded Acceleron Pharma as CEO with scientists Jasbir Seehra, Tom Maniatis , Mark Ptashne , Wylie Vale , and scientific advisor Joan Massague , and John Knopf.

4. John Maraganore - Wikipedia

   en.wikipedia.org/wiki/John_Maraganore

   The fifth RNAi therapeutic medicine, AMVUTTRA, was approved in 2021. At Alnylam, he forged over 25 major partnerships with leading pharmaceutical and biotechnology companies, raised over $7.5 billion to fund the company’s research, development, manufacturing, and commercialization activities, and built $25 billion in market capitalization value.

5. Alnylam Provides Key 2013 - 2014 Goals for RNAi ... - AOL

   www.aol.com/news/2013-01-06-alnylam-provides-key...

   CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today its key "Alnylam 5x15™" pipeline and partner program goals ...

6. The Medicines Company and Alnylam Form Strategic ... - AOL

   www.aol.com/news/2013-02-04-the-medicines...

   PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- The Medicines Company (NAS: MDCO) and Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today that ...

7. Alnylam's Biggest Opportunities - AOL

   www.aol.com/news/2013-10-01-alnylams-biggest...

   Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a biotech company developing a new class of medications based on RNAi technology, have soared 250% since the start of 2013. Why are investors so ...

8. Yvonne Greenstreet - Wikipedia

   en.wikipedia.org/wiki/Yvonne_Greenstreet

   Greenstreet became Alnylam's chief operating officer in 2016. In 2021, it was announced that John Maraganore would step down as Alnylam's CEO on 1 January 2022, and would be succeeded by Greenstreet. [1]

9. Alnylam Presents New Pre-clinical Data on RNAi Therapeutics ...

   www.aol.com/news/2012-11-14-alnylam-presents-new...

   CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi ...